Dr. Markman Discusses Diagnostic Molecular Testing

Maurie Markman, MD
Published: Wednesday, Nov 30, 2011

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, explains the shift in diagnostic tools towards molecular testing.

Cancer treatment is moving towards a molecular diagnostic paradigm. Various forms of diagnostic testing have been used for quite some time but only recently the type of testing has become more molecularly based. Very detailed molecular profiles of each individual's cancer can help determine a cure, spread of the disease, and the efficacy of therapy.

Markman believes that molecular diagnostics are revolutionary and will bring about more changes in cancer care than the past 100 years of cancer management advances.

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, explains the shift in diagnostic tools towards molecular testing.

Cancer treatment is moving towards a molecular diagnostic paradigm. Various forms of diagnostic testing have been used for quite some time but only recently the type of testing has become more molecularly based. Very detailed molecular profiles of each individual's cancer can help determine a cure, spread of the disease, and the efficacy of therapy.

Markman believes that molecular diagnostics are revolutionary and will bring about more changes in cancer care than the past 100 years of cancer management advances.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x